On Oct. 14, 2021, Regeneron announced that the U.S. Food and Drug Administration (FDA) had accepted for priority review a Biologics License Application for REGEN-COVﾮ (casirivimab and imdevimab) to treat COVID-19 in non-hospitalized patients and as prophylaxis in certain individuals.

The FDA assigned a target action date of April 13, 2022.